Chemopreventive effect of n-3 PUFAs and Atorvastatin in rats with bladder cancer

Pharmaceutical Regulatory Affairs: Open Access

ISSN: 2167-7689

Open Access

Chemopreventive effect of n-3 PUFAs and Atorvastatin in rats with bladder cancer

9th Annual European Pharma Congress

June 26-28, 2017 Madrid, Spain

Eman G Khedr, Nahla E El Ashmawy, Hoda A El Bahrawy and Samar M Al Tantawy

Tanta University, Egypt

Posters & Accepted Abstracts: Pharmaceut Reg Affairs

Abstract :

Bladder cancer remains a huge concern for the medical community because of its incidence and prevalence rates, as well as high percentage of recurrence and progression. Omega├ó┬?┬?3 polyunsatu├?┬Črated fatty acids (n├ó┬?┬?3 PUFAs) and atorvastatin (ATOR) proved anti-inflammatory effects through PPAR-├?┬│ mechanism. However, their chemopreventive effect still remained to be examined and clari├?┬Čfied. In the current study, bladder cancer was induced in rats by the chemical carcinogen BBN. n-3 PUFAs (DHA and EPA 2:3 w/w; 1200 mg/kg) and/or ATOR (6 mg/kg) were given orally daily to rats for 8 consecutive weeks concomitantly with BBN, and continued for further 4 weeks after cessa-tion of BBN administration. The histopathological examination of rat bladder revealed presence of tumors and absence of apoptotic bodies in sections from BBN group, while tumors were absent and apoptotic bodies were clearly observed in sections from rat groups treated with n-3 PUFAs, ATOR, or both drugs. The study of the molecular mechanisms illustrated downregulation of COX-2 and P53 (mutant) genes and suppression of TGF├ó┬?┬?├?┬▓1 and the lipid peroxidation product malondialdehyde in serum of rats of the three treated groups. This chemopreventive effect was confirmed by and associ├?┬Čated with lower level of bladder tumor antigen (BTA) in urine. However, the combined treatment with both drugs exhibited the major protective effect and nearly corrected the dyslipidemia that has been induced by BBN. Collectively, n-3PUFAs and ATOR, besides having anti-inflammatory proper-ties, proved a chemopreventive effect against bladder cancer, which nominates them to be used as adjuvant therapy with other chemotherapeutics.

Biography :


Google Scholar citation report
Citations: 533

Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report

Pharmaceutical Regulatory Affairs: Open Access peer review process verified at publons

Indexed In

arrow_upward arrow_upward